Moderna: A Most Peculiar Case of Post-Pandemic Existence

The arrival of the COVID-19 pandemic was, let’s be honest, a bit of a shock to everyone. A global event of that magnitude tends to disrupt things. (Like, for example, the carefully calibrated supply chains for artisanal toast.) Moderna, with its aforementioned microscopic robot technology, managed to produce a vaccine in record time. The result? A revenue jump from roughly $60 million to over $19 billion in 2023. This is, statistically speaking, a rather large number. It’s the kind of number that makes accountants slightly dizzy and venture capitalists exceptionally cheerful.








